Cowen analyst Marc Frahm reiterated an Outperform rating on Incyte (NASDAQ: INCY) ahead of Phase II data for topical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE